Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,258 | 6-8 weeks | |
50 mg | Inquiry | 6-8 weeks | |
100 mg | Inquiry | 6-8 weeks |
Description | Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) is the (S)-enantiomer of BAY-1143572. Atuveciclib S-Enantiomer is a potent and selective CDK9 inhibitor, which inhibits CDK9 / CycT1 with an IC 50 of 16 nM. |
In vitro | Atuveciclib (BAY-1143572) S-Enantiomer reveals very similar in vitro properties compared with Atuveciclib (BAY-1143572), well within the limits of measurement accuracy. However, with multiple batches of Atuveciclib (BAY-1143572) S-Enantiomer, there is a trend toward a slightly lower activity against CDK9 in the biochemical assay (IC 50 CDK9/CycT1: 16 nM) and antiproliferative activity against HeLa cells (IC 50 : 1100 nM) [1]. |
In vivo | Atuveciclib (BAY-1143572) S-Enantiomer exhibits blood/plasma ratios close to 1, suggesting a similarity in distribution. Compared to its parent compound, Atuveciclib (BAY-1143572), this enantiomer demonstrates comparable pharmacokinetic (PK) properties in rats, including a clearance rate (CL b) of 1.2 L/kg per hour, a steady-state volume of distribution (V ss) of 1.2 L/kg, a half-life (t 1/2) of 0.6 hours, and a bioavailability (F) of 53% [1]. |
Alias | BAY-1143572 S-Enantiomer |
Molecular Weight | 387.43 |
Formula | C18H18FN5O2S |
Cas No. | 2250279-81-1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 113 mg/mL (291.67 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.